KIORA PHARMACEUTICALS INC Stock Price, News & Analysis

Kiora Pharmaceuticals (NASDAQ: KPRX) announced on October 30, 2025 that it joined Global Genes' RARE-X Vision Consortium, a corporate‑nonprofit collaboration to accelerate research and development of therapies for rare ocular disorders.

The consortium will build a de‑identified, individual‑level global data repository to support patient identification and recruitment, define meaningful outcome measures by aggregating functional, structural, and patient‑reported data, and promote inclusive study design with patient input. Kiora's CEO, Brian Strem, said the collaboration aims to increase the probability of advancing Kiora's experimental inherited retinal disease therapy toward patients.

Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two ophthalmology events in October 2025 to discuss its development pipeline and industry trends. Maxim Growth Summit in New York: Brian M. Strem, PhD, President and CEO, will speak on an ophthalmology panel titled "A vision of innovation" on October 22, 2025 at 3:00 PM EDT (panel overview link: maximgrp.com/2025-growth-summit).

Eyecelerator @ AAO 2025 in Orlando: Eric Daniels, MD, MBA, Chief Development Officer, will present in the Poster Retina Showcase on October 16, 2025 at 1:45 PM EDT (program link: eyecelerator.com/aao-2025-program).

Kiora Pharmaceuticals (NASDAQ:KPRX) announced that CFO Melissa Tosca will present the company's pipeline of therapies for inherited and inflammatory retinal diseases at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

The presentation is scheduled for September 5th, 2025, at 7:00 am EDT. Investors can access the presentation through the company's investor relations website, where it will remain available on-demand for 90 days.

Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2025 financial results and pipeline updates for retinal disease treatments. The company initiated two Phase 2 clinical trials: KLARITY for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa). Kiora secured a potential $110M partnership with Senju Pharmaceutical for KIO-301 development in Asia.

Financial highlights include a $20.7M cash position, with additional $2.4M in collaboration receivables and $0.7M in tax credits. The company reported a net loss of $2.2M in Q2 2025, unchanged from Q2 2024. R&D expenses increased to $2.6M (before $1.7M in reimbursements), while G&A expenses decreased to $1.4M. Cash runway extends into late 2027, beyond anticipated clinical trial readouts.

Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. President and CEO Brian M. Strem, Ph.D. will present the company's pipeline of therapies focused on inherited and inflammatory retinal diseases.

The presentation is scheduled for Wednesday, August 13, 2025, at 7:00 am EDT. Investors can access the presentation through Kiora's investor relations website, with the replay remaining available for 90 days following the event.

Vicarious Surgical (NYSE: RBOT) has appointed Stephen From as its new Chief Executive Officer and Board member, effective August 7, 2025. Current CEO and Co-Founder Adam Sachs will transition to the role of President while remaining on the Board. From brings over 20 years of healthcare and financial industry leadership experience, most recently serving as CEO of Aruna Bio.

From's extensive background includes serving as President, CEO, and Executive Chairman of Kiora Pharmaceuticals, where he led the company through its IPO and multiple acquisitions. He previously held positions as CFO of Centelion SAS and worked in investment banking at Bank of America Securities and Robertson Stephens.

As part of his appointment, From will receive a stock option award for 297,600 shares of Class A common stock, vesting over four years, as a material inducement to his employment.

Kiora Pharmaceuticals (NASDAQ: KPRX) has been granted US Patent No. 12,364,680 for KIO-104, expanding its protection for treating various ocular diseases. The patent covers treatment applications including ocular inflammation, uveitis, age-related macular degeneration, and refractive surgery complications, extending market exclusivity until 2043.

The company is currently conducting a Phase 2 clinical trial (KLARITY study) investigating KIO-104 in up to 28 patients at two dose levels for inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema. KIO-104 functions by inhibiting the DHODH enzyme, reducing T-cell replication and inflammation.

Kiora Pharmaceuticals (NASDAQ: KPRX) has granted Senju Pharmaceutical an exclusive option for the development and commercialization of KIO-301, a molecular photoswitch therapy for retinal diseases, in key Asian markets including Japan and China. The deal has a potential value of $110 million plus royalties, starting with an immediate $1.25 million option fee. If exercised, Kiora will receive an additional mid-single digit million upfront payment plus development, regulatory, and commercial milestones. This agreement complements Kiora's existing partnership with Théa Open Innovation for markets outside Asia, bringing the total potential value of strategic partnerships to over $400 million plus royalties. KIO-301 is currently in the ABACUS-2 Phase 2 clinical trial, targeting 36 patients with ultra-low vision or no light perception due to retinitis pigmentosa. The therapy aims to restore visual function by targeting surviving retinal ganglion cells.

Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q1 2025 financial results and pipeline updates for retinal disease treatments. The company ended Q1 with $24.1 million in cash and expects to fund operations into late 2027. Key developments include approval to initiate two Phase 2 trials: KLARITY (evaluating KIO-104 for retinal inflammation) and ABACUS-2 (testing KIO-301 in retinitis pigmentosa patients). The company reported a net loss of $2.2 million compared to net income of $13.4 million in Q1 2024, with the difference mainly due to a $16 million upfront payment from Laboratoires Théa in 2024. R&D expenses were $2.5 million before $1.3 million in reimbursements, while G&A expenses increased to $1.5 million. Kiora received $1.8 million in reimbursed Q4 2024 R&D expenses from Théa Open Innovation.